The U.S. Food and Drug Administration approved zenocutuzumab-zbco for advanced cholangiocarcinoma, creating a new treatment option for patients with rare cancers. The approval targets adults with advanced, unresectable, or metastatic cholangiocarcinoma carrying a neuregulin 1 gene fusion after prior systemic therapy failure.
The new drug approved by regulators under the name Bizengri responds to an urgent need in treating patients with bile duct cancer. According to the regulators, NRG1 fusion-positive cholangiocarcinoma is an extremely rare and life-threatening malignancy with limited targeted therapies currently available. Consequently, many oncologists view the approval as an important advancement for precision oncology.
According to the FDA, zenocutuzumab-zbco is intended for patients whose disease has progressed following previous systemic treatments. The agency announced the approval after reviewing clinical evidence supporting the drug’s effectiveness and safety profile. Zenocutuzumab-zbco is a HER2- and HER3-directed bispecific antibody used to target tumors with mutations in the NRG1 gene fusions. Researchers believe the therapy interrupts signaling pathways responsible for tumor growth and survival. Therefore, the medicine may help slow disease progression in carefully selected patients.
The approval expands the growing role of biomarker-based therapies in oncology. In recent years, healthcare practitioners have widely embraced genomic analysis to determine eligibility for highly targeted drugs. As such, drugs like zenocutuzumab-zbco continue reshaping treatment approaches across several aggressive cancers. Clinical evidence in support of the efficacy of zenocutuzumab-zbco showed promising results among patients suffering from advanced stages of the disease. Investigators evaluated outcomes through the ongoing Phase 2 eNRGy clinical trial, which examined the therapy in solid tumors carrying NRG1 fusions. Regulators used these data during the approval review process.
Experts noted that cholangiocarcinoma often remains difficult to diagnose during early stages. Consequently, many patients receive diagnoses only after the cancer spreads or becomes surgically unresectable. Treatment options historically included chemotherapy, immunotherapy, or palliative care, while targeted therapies remained limited for rare molecular subtypes.
Based on statistics provided by the American Cancer Society, almost 8,000 individuals in the United States are diagnosed with bile duct cancer each year. This number comprises both intrahepatic bile duct cancers and extrahepatic bile duct cancers. However, experts believe the actual number could be higher because physicians often struggle to diagnose these cancers accurately.
Specialists explained that some bile duct cancer cases may be misclassified as other forms of cancer because symptoms frequently overlap. Additionally, the disease mainly affects older adults, although younger individuals can also develop the condition. The average age of patients diagnosed with bile duct cancer in the United States is typically in the 70s.
The FDA stated that zenocutuzumab-zbco specifically benefits patients whose tumors test positive for NRG1 gene fusions. Therefore, physicians must conduct molecular testing before prescribing the therapy. Precision testing is increasingly more important in making decisions on cancer treatments since targeted drugs work best in genetically defined populations.
Industry analysts believe the approval may encourage broader adoption of genomic screening among cholangiocarcinoma patients. Furthermore, there has been a huge investment by biotech firms in treatments meant for smaller patient pools, which have specific genetic alterations. This contributes to the growing market for precision medicine globally.
Partner Therapeutics received approval for Bizengri following the submission of a supplemental biologics license application. The company highlighted the severe unmet need among patients with NRG1 fusion-positive cholangiocarcinoma and emphasized the importance of providing new targeted treatment opportunities. Additionally, this therapy was recognized by the FDA in the Commissioner’s National Priority Voucher pilot program. This program is designed to accelerate the development and evaluation of drugs that tackle national health concerns and significant medical needs.
Importantly, zenocutuzumab-zbco already received accelerated approval in December 2024 for adult patients with advanced NSCLC and pancreatic adenocarcinoma with NRG1 fusion genes. Therefore, the recent approval is an expansion of the drug’s application in rare tumors with this genetic abnormality. Oncology specialists expect additional research involving zenocutuzumab-zbco to continue over the coming years. Researchers are assessing the potential uses of the drug for a wider array of patients. On the other hand, clinical trials remain essential for ensuring that aggressive gastrointestinal cancer patients have better chances of survival.
The approval also reflects growing momentum behind rare cancer drug development. Pharmaceutical companies increasingly pursue therapies targeting uncommon genetic drivers because advances in molecular diagnostics enable more accurate patient identification. Thus, personalized medicine approaches will continue gaining importance in oncology models worldwide.
Although healthcare practitioners maintain that cholangiocarcinoma remains an elusive form of cancer, even with the current medical advances, the FDA’s endorsement of drugs like zenocutuzumab-zbco provides optimism for patients with limited therapy options. Personalized medicine is considered one approach that may greatly enhance long-term outcomes for individuals with genetically defined tumors. The FDA advised healthcare professionals to review prescribing details carefully before starting the administration of zenocutuzumab-zbco, as well as determine patient suitability with proper diagnosis, along with monitoring safety measures associated with the therapy process.
As precision oncology continues advancing, zenocutuzumab-zbco may become another landmark in the transition from biomarker-based treatment of cancer. The recent FDA approval clearly highlights the dedication of the healthcare sector to creating novel treatment options for individuals suffering from uncommon and hard-to-treat cancers.
